Form 4 for GNLX GENELUX Corp
Accepted 2023-08-30 00:00:00 ET · period of report 2023-08-30 · accession 0001209191-23-047784 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-30 | 2023-08-30 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $24.70 | -19.8K | 135.9K | -13% | -$489.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-30 | S | D | 19,800 | $24.70 | 135,935 | D | — | — | (F1) The weighted average sale price for the transaction reported was $24.70, and the range of prices were between $24.70 and $24.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |